NZ585080A - Composition comprising Vitamin B12 and N-[8-(2-hydroxybenzoyl) amino ]caprylic acid and salts thereof for treating Vitamin B12 deficiency - Google Patents
Composition comprising Vitamin B12 and N-[8-(2-hydroxybenzoyl) amino ]caprylic acid and salts thereof for treating Vitamin B12 deficiencyInfo
- Publication number
- NZ585080A NZ585080A NZ585080A NZ58508008A NZ585080A NZ 585080 A NZ585080 A NZ 585080A NZ 585080 A NZ585080 A NZ 585080A NZ 58508008 A NZ58508008 A NZ 58508008A NZ 585080 A NZ585080 A NZ 585080A
- Authority
- NZ
- New Zealand
- Prior art keywords
- vitamin
- pharmaceutical composition
- hydroxybenzoyl
- deficiency
- snac
- Prior art date
Links
- 229930003779 Vitamin B12 Natural products 0.000 title claims abstract description 37
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 title claims abstract description 37
- 235000019163 vitamin B12 Nutrition 0.000 title claims abstract description 37
- 239000011715 vitamin B12 Substances 0.000 title claims abstract description 37
- 239000000203 mixture Substances 0.000 title claims abstract description 17
- 150000003839 salts Chemical class 0.000 title claims abstract description 14
- 208000002670 vitamin B12 deficiency Diseases 0.000 title claims abstract description 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 title abstract description 8
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 title abstract description 6
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 title abstract description 3
- 229960002446 octanoic acid Drugs 0.000 title abstract description 3
- FCCDDURTIIUXBY-UHFFFAOYSA-N lipoamide Chemical compound NC(=O)CCCCC1CCSS1 FCCDDURTIIUXBY-UHFFFAOYSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 30
- 238000011282 treatment Methods 0.000 claims abstract description 24
- 239000000126 substance Substances 0.000 claims abstract description 12
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims abstract description 7
- 239000011734 sodium Substances 0.000 claims abstract description 7
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 7
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 claims abstract description 5
- 229940088594 vitamin Drugs 0.000 claims description 36
- 229930003231 vitamin Natural products 0.000 claims description 36
- 235000013343 vitamin Nutrition 0.000 claims description 36
- 239000011782 vitamin Substances 0.000 claims description 36
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 36
- 239000002253 acid Substances 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 15
- 229930003270 Vitamin B Natural products 0.000 claims description 11
- 230000007812 deficiency Effects 0.000 claims description 11
- 235000019156 vitamin B Nutrition 0.000 claims description 11
- 239000011720 vitamin B Substances 0.000 claims description 11
- 239000003086 colorant Substances 0.000 claims description 9
- 239000003085 diluting agent Substances 0.000 claims description 9
- 239000003995 emulsifying agent Substances 0.000 claims description 9
- 239000000796 flavoring agent Substances 0.000 claims description 9
- 235000013355 food flavoring agent Nutrition 0.000 claims description 9
- 235000003599 food sweetener Nutrition 0.000 claims description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- 239000003381 stabilizer Substances 0.000 claims description 9
- 239000003765 sweetening agent Substances 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 230000003247 decreasing effect Effects 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000003826 tablet Substances 0.000 description 46
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 38
- UOENJXXSKABLJL-UHFFFAOYSA-M sodium;8-[(2-hydroxybenzoyl)amino]octanoate Chemical compound [Na+].OC1=CC=CC=C1C(=O)NCCCCCCCC([O-])=O UOENJXXSKABLJL-UHFFFAOYSA-M 0.000 description 36
- 235000000639 cyanocobalamin Nutrition 0.000 description 19
- 239000011666 cyanocobalamin Substances 0.000 description 19
- 229960002104 cyanocobalamin Drugs 0.000 description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 7
- OAYRYNVEFFWSHK-UHFFFAOYSA-N carsalam Chemical compound C1=CC=C2OC(=O)NC(=O)C2=C1 OAYRYNVEFFWSHK-UHFFFAOYSA-N 0.000 description 6
- -1 hydroxybenzoyl Chemical group 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 229950004289 carsalam Drugs 0.000 description 5
- GHBFNMLVSPCDGN-UHFFFAOYSA-N rac-1-monooctanoylglycerol Chemical compound CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 description 5
- 201000010099 disease Diseases 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000012369 In process control Methods 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 3
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000010965 in-process control Methods 0.000 description 3
- 229940029329 intrinsic factor Drugs 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 229940045999 vitamin b 12 Drugs 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- 229920003082 Povidone K 90 Polymers 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- SKZKKFZAGNVIMN-UHFFFAOYSA-N Salicilamide Chemical compound NC(=O)C1=CC=CC=C1O SKZKKFZAGNVIMN-UHFFFAOYSA-N 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 210000000133 brain stem Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- YOZNUFWCRFCGIH-BYFNXCQMSA-L hydroxocobalamin Chemical compound O[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O YOZNUFWCRFCGIH-BYFNXCQMSA-L 0.000 description 2
- 210000003405 ileum Anatomy 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 229960000581 salicylamide Drugs 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 102000011409 Transcobalamins Human genes 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- GWCQSPUAEOPDKF-UHFFFAOYSA-N amino octanoate Chemical compound CCCCCCCC(=O)ON GWCQSPUAEOPDKF-UHFFFAOYSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229940010007 cobalamins Drugs 0.000 description 1
- 150000001867 cobalamins Chemical class 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000004136 fatty acid synthesis Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001914 gastric parietal cell Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 235000004867 hydroxocobalamin Nutrition 0.000 description 1
- 239000011704 hydroxocobalamin Substances 0.000 description 1
- 229960001103 hydroxocobalamin Drugs 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000007672 methylcobalamin Nutrition 0.000 description 1
- 239000011585 methylcobalamin Substances 0.000 description 1
- JEWJRMKHSMTXPP-BYFNXCQMSA-M methylcobalamin Chemical compound C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O JEWJRMKHSMTXPP-BYFNXCQMSA-M 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000001711 oxyntic cell Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98489807P | 2007-11-02 | 2007-11-02 | |
| US2010808P | 2008-01-09 | 2008-01-09 | |
| US8356608P | 2008-07-25 | 2008-07-25 | |
| PCT/US2008/082064 WO2009059188A1 (en) | 2007-11-02 | 2008-10-31 | Method of treating vitamin b12 deficiency |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ585080A true NZ585080A (en) | 2012-05-25 |
Family
ID=40591491
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ585080A NZ585080A (en) | 2007-11-02 | 2008-10-31 | Composition comprising Vitamin B12 and N-[8-(2-hydroxybenzoyl) amino ]caprylic acid and salts thereof for treating Vitamin B12 deficiency |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US8022048B2 (enExample) |
| EP (1) | EP2215047B1 (enExample) |
| JP (1) | JP5555634B2 (enExample) |
| KR (1) | KR101344369B1 (enExample) |
| CN (1) | CN101952241B (enExample) |
| AU (1) | AU2008318423B2 (enExample) |
| BR (1) | BRPI0817396C8 (enExample) |
| CA (1) | CA2704780C (enExample) |
| CL (1) | CL2010000434A1 (enExample) |
| CO (1) | CO6280475A2 (enExample) |
| DK (1) | DK2215047T3 (enExample) |
| ES (1) | ES2443817T3 (enExample) |
| MX (1) | MX2010004716A (enExample) |
| NZ (1) | NZ585080A (enExample) |
| PL (1) | PL2215047T3 (enExample) |
| PT (1) | PT2215047E (enExample) |
| RU (1) | RU2469728C2 (enExample) |
| WO (1) | WO2009059188A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5985985B2 (ja) * | 2009-08-03 | 2016-09-06 | エミスフィアー テクノロジーズ インコーポレイテッドＥｍｉｓｐｈｅｒｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ，Ｉｎｃ． | 胃腸への影響が減少した即効型ナプロキセン組成物 |
| KR20130026429A (ko) * | 2010-02-24 | 2013-03-13 | 에미스페어 테크놀로지스, 인코포레이티드 | 경구 ｂ12 치료요법 |
| RS56998B1 (sr) | 2010-12-16 | 2018-05-31 | Novo Nordisk As | Čvrste kompozicije koje sadrže agonist glp-1 i so n-(8-(2-hidroksibenzoil)amino)kaprilne kiseline |
| EP2696687B1 (en) | 2011-04-12 | 2016-10-26 | Novo Nordisk A/S | Double-acylated glp-1 derivatives |
| US8805208B2 (en) * | 2012-02-03 | 2014-08-12 | Tyco Electronics Subsea Communications Llc | System and method for polarization de-multiplexing in a coherent optical receiver |
| CN104203266B (zh) | 2012-03-22 | 2017-12-26 | 诺和诺德股份有限公司 | Glp‑1肽组合物及其制备 |
| ES2965469T3 (es) | 2012-03-22 | 2024-04-15 | Novo Nordisk As | Composiciones que comprenden un agente de suministro y preparación de estas |
| DK2827845T3 (en) | 2012-03-22 | 2019-04-01 | Novo Nordisk As | COMPOSITIONS INCLUDING A PROCEDURE AND PREPARING THEREOF |
| CN104487056A (zh) | 2012-06-20 | 2015-04-01 | 诺和诺德A/S（股份有限公司） | 包含肽和递送剂的片剂制剂 |
| US20140309270A1 (en) | 2013-04-11 | 2014-10-16 | Richard Louis Price | Diagnosis and treatment of a form of autistic spectrum disorder |
| US9211284B2 (en) | 2013-04-11 | 2015-12-15 | Richard Louis Price | Diagnosis and treatment of P.R.I.C.E. syndrome |
| US20170348417A1 (en) | 2013-04-11 | 2017-12-07 | Richard Louis Price | Treatment of attention deficit disorders and associated symptoms |
| US9603812B2 (en) | 2013-04-11 | 2017-03-28 | Richard Louis Price | Treatment of autistic spectrum disorder |
| US10098848B2 (en) | 2013-04-11 | 2018-10-16 | Richard Louis Price | Inositol-containing comestible units and methods of treatment using the same |
| BR112015026325A2 (pt) | 2013-05-02 | 2017-07-25 | Novo Nordisk As | dosagem oral de compostos glp-1 |
| MX382853B (es) | 2016-04-22 | 2025-03-13 | Spoke Sciences Inc | Compuestos medicinales y suplementos nutricionales de base vegetal de rápida acción. |
| EA201892396A1 (ru) | 2016-12-02 | 2019-04-30 | Ресептор Лайф Сайенсиз, Инк. | Быстродействующие растительные лекарственные соединения и биологически активные добавки |
| US20200254041A1 (en) * | 2017-10-05 | 2020-08-13 | Receptor Holdings, Inc. | Rapid onset and extended action plant-based and synthetic cannabinoid formulations |
| US20200268821A1 (en) * | 2017-10-05 | 2020-08-27 | Receptor Holdings, Inc. | Herbal compositions with improved bioavailability |
| WO2019149880A1 (en) | 2018-02-02 | 2019-08-08 | Novo Nordisk A/S | Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant |
| AU2019385420A1 (en) | 2018-11-19 | 2021-07-08 | Spoke Sciences, Inc. | N-acylated fatty amino acids to reduce absorption variability in cannabinoid based compositions |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5665379A (en) * | 1990-09-28 | 1997-09-09 | Pharmacia & Upjohn Aktiebolag | Lipid particle forming matrix, preparation and use thereof |
| US5474978A (en) | 1994-06-16 | 1995-12-12 | Eli Lilly And Company | Insulin analog formulations |
| US5650386A (en) * | 1995-03-31 | 1997-07-22 | Emisphere Technologies, Inc. | Compositions for oral delivery of active agents |
| CA2266412A1 (en) * | 1996-09-18 | 1998-03-26 | William J. Sarill | Compositions containing cobalamin and amino acids |
| US5773647A (en) | 1997-02-07 | 1998-06-30 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| MXPA01006297A (es) * | 1998-12-28 | 2002-06-04 | Biogentec Inc | Tratamiento con cianocobalamina (vitamina b12) para enfermedades alergicas. |
| IL145546A0 (en) | 1999-04-05 | 2002-06-30 | Emisphere Tech Inc | Disodium salts, monohydrates, and ethanol solvates for delivering active agents |
| EP1535625B1 (en) | 1999-04-05 | 2014-01-08 | Novartis AG | Composition containing n-(5-chlorosalicyloyl)-8-aminocaprylic acid and salmon calcitonin |
| JP4799794B2 (ja) * | 2000-03-21 | 2011-10-26 | エミスフェアー・テクノロジーズ・インク | ジカルボキシル化中間体を介してアルキル化サリチルアミドを調製する方法。 |
| US7049283B2 (en) | 2000-12-06 | 2006-05-23 | Novartis Ag | Pharmaceutical compositions for the oral delivery of pharmacologically active agents |
| CA2446929C (en) | 2001-06-01 | 2013-04-09 | Novartis Ag | Orally administering parathyroid hormone and calcitonin |
| JP4959917B2 (ja) | 2001-08-17 | 2012-06-27 | ノバルティス アーゲー | 副甲状腺ホルモンフラグメント用経口送達剤としての５−ｃｎａｃ |
| US20050054557A1 (en) | 2002-05-09 | 2005-03-10 | Goldberg Michael M. | Compositions for delivering parathyroid hormone and calcitonin |
| TW200403052A (en) | 2002-07-17 | 2004-03-01 | Novartis Ag | Use of organic compounds |
| AR040737A1 (es) | 2002-08-01 | 2005-04-20 | Novartis Ag | Administracion oral de calcitonina |
| EP1545477A4 (en) | 2002-09-13 | 2006-11-22 | Cydex Inc | CAPSULES CONTAINING AQUEOUS FILLING COMPOSITIONS STABILIZED WITH DERIVED CYCLODEXTRIN |
| CN100579955C (zh) | 2003-04-04 | 2010-01-13 | 帝斯曼知识产权资产管理有限公司 | N-烷氧基草酰丙氨酸酯的制备方法 |
| US6938439B2 (en) | 2003-05-22 | 2005-09-06 | Cool Clean Technologies, Inc. | System for use of land fills and recyclable materials |
| JP3924616B2 (ja) | 2003-06-30 | 2007-06-06 | 独立行政法人物質・材料研究機構 | 微小サイズの温度感知素子を用いる温度計測方法 |
| EP1643978A1 (en) | 2003-07-04 | 2006-04-12 | Nycomed Danmark A/S | Parathyroid hormone (pth) containing pharmaceutical compositions for oral use |
| WO2005004900A1 (en) * | 2003-07-11 | 2005-01-20 | Novartis Ag | Orally dosed pharmaceutical compositions comprising a delivery agent in micronized form |
| US7749954B2 (en) | 2003-07-23 | 2010-07-06 | Novartis Ag | Use of calcitonin in osteoarthritis |
| JP4903690B2 (ja) * | 2004-05-06 | 2012-03-28 | エミスフェアー・テクノロジーズ・インク | Ｎ−［８−（２−ヒドリキシベンゾイル）アミノ］カプリル酸一ナトリウムの結晶多形体 |
| WO2006020291A2 (en) * | 2004-08-02 | 2006-02-23 | Bebaas, Inc. | Vitamin b12 compositions |
| JP2008509933A (ja) | 2004-08-13 | 2008-04-03 | エミスフェアー・テクノロジーズ・インク | 送達剤のマイクロ粒子またはナノ粒子を含む医薬製剤 |
| US20060116334A1 (en) * | 2004-12-01 | 2006-06-01 | Curt Hendrix | Folate based composition for treatment of the cardiovascular system |
| GB0427603D0 (en) | 2004-12-16 | 2005-01-19 | Novartis Ag | Organic compounds |
| GB0427600D0 (en) | 2004-12-16 | 2005-01-19 | Novartis Ag | Organic compounds |
| CA2626029A1 (en) * | 2005-11-04 | 2007-05-18 | Genta Incorporated | Pharmaceutical gallium compositions and methods |
-
2008
- 2008-10-31 KR KR1020107010771A patent/KR101344369B1/ko not_active Expired - Fee Related
- 2008-10-31 CA CA2704780A patent/CA2704780C/en not_active Expired - Fee Related
- 2008-10-31 RU RU2010118423/15A patent/RU2469728C2/ru active
- 2008-10-31 US US12/262,677 patent/US8022048B2/en not_active Expired - Fee Related
- 2008-10-31 MX MX2010004716A patent/MX2010004716A/es active IP Right Grant
- 2008-10-31 DK DK08844673.7T patent/DK2215047T3/da active
- 2008-10-31 WO PCT/US2008/082064 patent/WO2009059188A1/en not_active Ceased
- 2008-10-31 BR BRPI0817396A patent/BRPI0817396C8/pt not_active IP Right Cessation
- 2008-10-31 EP EP08844673.7A patent/EP2215047B1/en not_active Not-in-force
- 2008-10-31 PT PT88446737T patent/PT2215047E/pt unknown
- 2008-10-31 CN CN200880119724.0A patent/CN101952241B/zh not_active Expired - Fee Related
- 2008-10-31 PL PL08844673T patent/PL2215047T3/pl unknown
- 2008-10-31 JP JP2010532292A patent/JP5555634B2/ja not_active Expired - Fee Related
- 2008-10-31 ES ES08844673.7T patent/ES2443817T3/es active Active
- 2008-10-31 NZ NZ585080A patent/NZ585080A/en not_active IP Right Cessation
- 2008-10-31 AU AU2008318423A patent/AU2008318423B2/en not_active Ceased
-
2010
- 2010-04-30 CL CL2010000434A patent/CL2010000434A1/es unknown
- 2010-06-02 CO CO10066425A patent/CO6280475A2/es active IP Right Grant
-
2011
- 2011-08-09 US US13/206,090 patent/US8288360B2/en not_active Expired - Fee Related
-
2012
- 2012-09-14 US US13/618,654 patent/US8557792B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2008318423B2 (en) | Method of treating vitamin B12 deficiency | |
| US8802114B2 (en) | Pharmaceutical compositions of iron for oral administration | |
| EP2421525B1 (en) | Diclofenac formulation | |
| AU2015202842B2 (en) | Combination formulation of two antiviral compounds | |
| CN103751192A (zh) | 包含利拉列汀和任选的sglt2抑制剂的药物组合物及其用途 | |
| KR20150000872A (ko) | 시알산 결핍을 치료하기 위한 방법 및 제형 | |
| EP3972599B1 (en) | Combination for lowering serum phosphate in a patient | |
| US20100136109A1 (en) | Sustained release | |
| HK1146480B (en) | Method of treating vitamin b12 deficiency | |
| US20070065511A1 (en) | Controlled delivery creatine formulations and method of using the same | |
| WO2011053917A2 (en) | Gastroretentive oral high dose zinc preparations | |
| WO2006102748A1 (en) | Intravenous formulations of pyridoxal 5'-phosphate and method of preparation | |
| AU2014208310C1 (en) | A Novel Formulation of Diclofenac | |
| JP2022537106A (ja) | メトホルミン及びクエン酸カルシウムを含む医薬剤形 | |
| JP2024531639A (ja) | Ｆｘｒアゴニストの医薬組成物及びその製造方法 | |
| HK1252214A1 (en) | Diclofenac formulation | |
| HK1192160A (en) | Pharmaceutical composition comprising linagliptin and optionally a sglt2 inhibitor, and uses thereof | |
| HK1161674A (en) | Pharmaceutical composition comprising linagliptin and optionally a sglt2 inhibitor, and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 OCT 2016 BY THOMSON REUTERS Effective date: 20150922 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 OCT 2017 BY THOMSON REUTERS Effective date: 20160909 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 OCT 2018 BY THOMSON REUTERS Effective date: 20170919 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 OCT 2019 BY THOMSON REUTERS Effective date: 20180917 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 OCT 2020 BY THOMSON REUTERS Effective date: 20190917 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 OCT 2021 BY THOMSON REUTERS Effective date: 20200926 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 OCT 2022 BY ANAQUA SERVICES Effective date: 20210921 |
|
| LAPS | Patent lapsed |